A Phase II Study of INVAC-1 as Treatment of Patients With High-risk Chronic Lymphocytic Leukemia
Phase of Trial: Phase II
Latest Information Update: 01 Aug 2018
At a glance
- Drugs HTERT DNA vaccine Invectys (Primary) ; Ibrutinib
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors Invectys
- 31 Aug 2018 Biomarkers information updated
- 25 Jul 2018 Status changed from not yet recruiting to recruiting.
- 27 Feb 2018 Planned initiation date changed from 1 Dec 2017 to 1 May 2018.